• Orthox Ltd.

  Participated · Series A · Feb 2022

  Orthox is a clinical-stage company developing FibroFix™, a fibroin-based tissue scaffold derived from silk fibres that aims to emulate cartilage functional properties while facilitating rapid tissue regeneration. FibroFix implants are designed to be bone-sparing, enable strong tissue integration, and be implanted via minimally invasive surgical techniques to support faster patient rehabilitation. The company is preparing pivotal clinical trials for knee cartilage repair, with initial recruitment of a six-patient cohort (six months follow-up) before expanding to a 75-patient trial with two years of follow-up. Planned and proposed clinical sites include Southmead Hospital Bristol and sites in Budapest, Hungary; Orthox has submitted a regulatory dossier to the Hungarian authority OGYÉI. The business is clinical-stage and has raised capital and grants to support development; it employs 18 people at its site in Oxfordshire.

• Oxford Endovascular

  Participated · Series A · Apr 2021

  Oxford Endovascular is a medtech spin-out from Oxford University led by CEO Mike Karim that is developing OxiFlow (OXIFLOW), a next-generation flow-diverter for intracranial aneurysms. The device is designed to divert blood flow away from aneurysms at risk of rupture, place more accurately and safely than existing devices, and conform better to blood vessels to make more patients treatable. The company’s technology aims to reduce the risk of complications associated with current treatments for brain haemorrhage. Oxford Endovascular plans to use new funding to advance OxiFlow toward a First‑In‑Human clinical study and to scale up operations. The company highlights the clinical need by noting aneurysms affect about 1 in 50 persons. The description and plans above are drawn from the company’s recent announcement of its Series A+ round. Oxford Endovascular is developing OxiFlow™, a micro stent that uses ‘Origami’ engineering to be inserted via minimally invasive groin access and positioned across the base of a brain aneurysm to cause it to shrink and heal. The company is led by CEO Mike Karim and is a spin‑out from Oxford University. It raised $10m in a Series A to complete development work and to obtain first‑in‑human data through an early feasibility clinical study. The funds also aim to prepare the company for a subsequent larger fundraise to support FDA and CE Mark clinical trials. Oxford Endovascular plans to use those future trials to enter various international markets the article says are valued at over $1 billion. The company’s immediate focus is finishing development and generating initial clinical evidence to enable regulatory and commercial expansion.

No current team members are available.